Mymetics Corp (MYMX)

[bow-tie]

Our PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. PD1-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of colorectal cancer.

We have two HER2 B-cell immunotherapies in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both immunotherapies showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell immuno-therapy technology as well as suggesting therapeutic potential in HER2+ cancers.

https://www.imugene.com/technologies-introduction

Everyone knows were HER-VAXX came from MYMX